BioSig Technologies, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on April 13, 2021. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut. The report discloses a material event under Regulation FD regarding the Company's clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate development event rather than financial performance data.
Material Changes and Corporate Developments
- Clinical Trial Milestone: On April 13, 2021, the Company announced the completion of enrollment in the PURE EP 2.0 clinical trial.
- Disclosure Method: The announcement was made via a press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The filing includes standard disclaimers that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination of materiality under Regulation FD.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details regarding the PURE EP 2.0 trial design and next steps.
- Confirm the current status of the trial data readout or interim results, as this filing only confirms enrollment completion.
- Review recent 10-Q or 10-K filings for the most up-to-date financial position, as this 8-K contains no financial statements.